STOCK TITAN

Daxor Corporation (DXR) Financials

DXR
FY2011 annual
Revenue $1.4M -8.4% YoY
Net Income -$7.2M -244.6% YoY
EPS (Diluted) -$1.70 -245.3% YoY
Free Cash Flow -$6.6M n/m YoY
Market Cap $54.9M as of Oct 22, 2026
Price / Sales 37.9x on $1.4M revenue, FY2011
Price / Earnings n/m net loss, so no earnings multiple, FY2011
Price / Book 1.5x on $36.2M equity, Q4 FY2011

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2011, ended Dec 31, 2011 Reported Currency USD FYE December

Newest figures come from the 10-K for FY2011, filed Mar 28, 2012. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DXR SEC filings page.

Daxor Corporation (DXR) reported $1.4M in revenue for fiscal year 2011, down 8.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DXR FY2011

Daxor’s figures show a development-stage operation where research and overhead overwhelm a small revenue base despite positive gross margins.

Gross margin increased 1.0 pp as revenue fell 8.4%, separating product-level economics from the company’s broader cost structure. Operating margin deteriorated 41.7 pp to -400.1%, showing that the main constraint was spending required to operate, not the direct cost of sales.

The 2011 net loss of $7.19M was accompanied by operating cash flow of -$6.51M, so the earnings shortfall was broadly reflected in cash rather than being mainly a non-cash accounting effect. Meanwhile, liabilities rose 12.0% while assets fell 6.0%, indicating a less conservative financing structure.

R&D consumed 187.1% of revenue and SG&A consumed 267.9%, explaining why a gross profit of $794K could not support operations. Reported liquidity equaled 103 months of the latest annual outflow, a balance-sheet comparison that does not demonstrate operating self-sufficiency.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

Daxor Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress
1.32

Daxor Corporation scores 1.32, below the 1.81 distress threshold. The score is pulled down most by an operating loss of $5.8M against total assets of $85.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/8

Daxor Corporation passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Daxor Corporation reported a net loss of $7.2M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)
-$0.35
YoY-166.0%
QoQn/m

Daxor Corporation earned -$0.35 per diluted share (EPS) in Q4 2011. This represents a decrease of 166.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q4 2011.

EBITDA

Not reported for Q4 2011.

Net Income

Not reported for Q4 2011.

Cash & Balance Sheet

Free Cash Flow
-$995K
YoYn/m
QoQn/m

Daxor Corporation recorded an outflow of $995K in free cash flow in Q4 2011, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$60K
YoY+3.3%
QoQ+100.7%

Daxor Corporation held $60K in cash as of Q4 2011; no long-term debt figure is on record for that period.

Dividends Per Share
$0.10
YoY-84.6%

Daxor Corporation paid $0.10 per share in dividends in Q4 2011. This represents a decrease of 84.6% from the same quarter a year earlier.

Shares Outstanding
4M
YoY-0.7%
QoQ-0.4%

Daxor Corporation had 4M shares outstanding in Q4 2011. This represents a decrease of 0.7% from the same quarter a year earlier. Against the prior quarter it is down 0.4%.

Margins & Returns

None of these metrics is reported for Q4 2011.

Capital Allocation

Share Buybacks
$230K
YoY+3617.8%
QoQ+214974.8%

Daxor Corporation spent $230K on share buybacks in Q4 2011, returning capital to shareholders by reducing shares outstanding. This represents an increase of 3617.8% from the same quarter a year earlier. Against the prior quarter it is up 214974.8%.

Capital Expenditures
$5K
YoY-86.6%
QoQ-91.9%

Daxor Corporation invested $5K in capex in Q4 2011, funding long-term assets and infrastructure. This represents a decrease of 86.6% from the same quarter a year earlier. Against the prior quarter it is down 91.9%.

R&D Spending

Not reported for Q4 2011.

DXR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXR quarterly income statement
MetricQ4'1110-KQ3'1110-QQ2'1110-QQ4'1010-KQ3'1010-QQ2'1010-Q
RevenueN/A$341K-24.8%$358K-2.8%N/A$453K$368K
Cost of RevenueN/A$149K-19.6%$161K-2.8%N/A$186K$165K
Gross ProfitN/A$192K-28.4%$197K-2.7%N/A$268K$203K
R&D ExpensesN/A$637K-8.3%$670K-8.8%N/A$695K$735K
SG&A ExpensesN/A$816K-4.9%$871K-10.5%N/A$858K$973K
Operating IncomeN/A-$1.3Mn/m-$1.3Mn/mN/A-$1.3M-$1.5M
EBITDAN/A-$1.2Mn/mN/AN/A-$1.2MN/A
Interest ExpenseN/A$30K+46.5%$81K+811.1%N/A$20K$9K
Income TaxN/A-$2.8M-258.1%-$182Kn/mN/A$1.8M-$40K
Net IncomeN/A-$4.2M-260.6%-$185K-198.0%N/A$2.6M$188K
EPS (Basic)-$0.35-166.0%-$0.99-259.7%-$0.04-200.0%$0.53$0.62$0.04
EPS (Diluted)-$0.35-166.0%-$0.99-259.7%-$0.04-200.0%$0.53$0.62$0.04

Not reported in any period shown, so not listed: Diluted Shares (Avg).

DXR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXR quarterly balance sheet
MetricQ4'1110-KQ3'1110-QQ2'1110-QQ4'1010-KQ3'1010-QQ2'1010-Q
Total Assets$85.7M-6.0%$88.3M$96.2M$91.2MN/AN/A
Current Assets$81.7M-6.1%$84.1M$92.1M$87.0MN/AN/A
Cash & Equivalents$60K+3.3%$30K-72.2%$112K-47.6%$58K$107K$213K
Short-Term Investments$55.8M+3.6%$52.3Mn/m$54.1Mn/m$53.9M$0$0
Inventory$302K-17.1%$313K$357K$364KN/AN/A
Accounts Receivable$220K+22.9%$190K$193K$179KN/AN/A
Long-Term Investments$0n/m$0n/m$0n/m$0$0$0
Total Liabilities$49.5M+12.0%$50.6M$50.7M$44.2MN/AN/A
Current Liabilities$49.3M+12.2%$50.4M$50.4M$43.9MN/AN/A
Non-Current Liabilities$244K-18.7%$259K$273K$300KN/AN/A
Total Equity$36.2M-22.9%$37.6M$45.6M$47.0MN/AN/A
Retained Earnings$24.7M-25.0%$26.7M$30.8M$33.0MN/AN/A

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

DXR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXR quarterly cash flow statement
MetricQ4'1110-KQ3'1110-QQ2'1110-QQ4'1010-KQ3'1010-QQ2'1010-Q
Operating Cash Flow-$990Kn/m-$613Kn/mN/A-$1.8M-$1.2MN/A
Depreciation & Amortization$71K-3.4%$72K-2.0%N/A$74K$74KN/A
Capital Expenditures$5K-86.6%$58K-35.8%N/A$35K$91KN/A
Free Cash Flow-$995Kn/m-$671Kn/mN/A-$1.9M-$1.3MN/A
Investing Cash Flow-$8.1M-224.8%-$3.3Mn/mN/A$6.5M-$109KN/A
Financing Cash Flow$9.1Mn/m$3.8M+210.8%N/A-$4.7M$1.2MN/A
Dividends Paid$421K-84.7%$0-100.0%N/A$2.7M$1.1MN/A
Share Buybacks$230K+3617.8%$107-99.9%N/A$6K$126KN/A

Not reported in any period shown, so not listed: Stock-Based Compensation.

DXR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXR quarterly financial ratios
MetricQ4'1110-KQ3'1110-QQ2'1110-QQ4'1010-KQ3'1010-QQ2'1010-Q
Gross MarginN/A56.2%-2.8pp55.1%0.0ppN/A59.0%55.1%
Operating MarginN/A-369.9%-375.2%N/A-283.5%-408.6%
Net MarginN/A-1227.2%-51.5%-102.7ppN/A574.7%51.1%
Return on EquityN/A-11.1%-0.4%N/AN/AN/A
Return on AssetsN/A-4.7%-0.2%N/AN/AN/A
Current Ratio1.66-0.3x1.671.831.98N/AN/A
Liabilities-to-Equity1.37+0.4x1.351.110.94N/AN/A
Asset TurnoverN/A0.000.00N/AN/AN/A
FCF MarginN/A-197.0%N/AN/A-289.7%N/A

Not reported in any period shown, so not listed: Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Daxor Corporation DXR FY2011 $1.4M -$7.2M N/A $54.9M —
JIN MEDICAL INTERNATIONAL LTD. ZJYL FY2025 $20.7M $1.2M 5.8% $148.8M 45/100
Pro-Dex Inc New PDEX FY2026 $77.5M $13.7M 17.6% $201.7M 72/100
Milestone Scientific, Inc. MLSS FY2025 $9.0M -$5.7M -63.8% $28.1M 40/100

Frequently Asked Questions

What is Daxor Corporation's annual revenue?

Daxor Corporation (DXR) reported $1.4M in total revenue for fiscal year 2011. This represents a -8.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Daxor Corporation's revenue growing?

Daxor Corporation (DXR) revenue declined by 8.4% year-over-year, from $1.6M to $1.4M in fiscal year 2011.

Is Daxor Corporation profitable?

No, Daxor Corporation (DXR) reported a net loss of $7.2M in fiscal year 2011.

Daxor Corporation (DXR) reported diluted earnings per share of -$1.70 for fiscal year 2011. This represents a -245.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Daxor Corporation (DXR) had EBITDA of -$5.5M in fiscal year 2011, measuring earnings before interest, taxes, depreciation, and amortization.

Daxor Corporation (DXR) had a gross margin of 54.9% in fiscal year 2011, indicating the percentage of revenue retained after direct costs of goods sold.

Yes, Daxor Corporation (DXR) paid $0.25 per share in dividends during fiscal year 2011.

Daxor Corporation (DXR) has a return on equity of -19.8% for fiscal year 2011, measuring how efficiently the company generates profit from shareholder equity.

Daxor Corporation (DXR) recorded an outflow of $6.6M in free cash flow during fiscal year 2011. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Daxor Corporation (DXR) recorded an outflow of $6.5M in operating cash flow during fiscal year 2011, representing cash used by core business activities.

Daxor Corporation (DXR) had $85.7M in total assets as of fiscal year 2011, including both current and long-term assets.

Daxor Corporation (DXR) invested $123K in capital expenditures during fiscal year 2011, funding long-term assets and infrastructure.

Daxor Corporation (DXR) invested $2.7M in research and development during fiscal year 2011.

Yes, Daxor Corporation (DXR) spent $230K on share buybacks during fiscal year 2011, returning capital to shareholders by reducing shares outstanding.

Daxor Corporation (DXR) had 4M shares outstanding as of fiscal year 2011.

Daxor Corporation (DXR) had a current ratio of 1.66 as of fiscal year 2011, which is generally considered healthy.

Daxor Corporation (DXR) had a liabilities-to-equity ratio of 1.37 as of fiscal year 2011, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2011, because the filing data we hold for that year carries no long-term debt figure.

Daxor Corporation (DXR) had a return on assets of -8.4% for fiscal year 2011, measuring how efficiently the company uses its assets to generate profit.

Daxor Corporation (DXR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2011). The market capitalization is $54.9M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Daxor Corporation (DXR) trades at 37.9x sales, its market capitalization divided by $1.4M revenue, FY2011. The market capitalization is $54.9M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2011, Daxor Corporation (DXR) held $55.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.5M over that year. Dividing the one by the other, the reported balance equals about 103 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Daxor Corporation (DXR) has an Altman Z-Score of 1.32, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Daxor Corporation (DXR) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Daxor Corporation (DXR) reported a net loss of $7.2M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top